- Conditions
- Ankylosing Spondylitis
- Interventions
- Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 859 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 19
- States / cities
- Mesa, Arizona • Escondido, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced May 21, 2026, 11:24 PM EDT